1,086 reports of this reaction
2.2% of all GALCANEZUMAB GNLM reports
#8 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #8 most commonly reported adverse reaction for GALCANEZUMAB GNLM, manufactured by Eli Lilly and Company. There are 1,086 FDA adverse event reports linking GALCANEZUMAB GNLM to INJECTION SITE ERYTHEMA. This represents approximately 2.2% of all 49,086 adverse event reports for this drug.
Patients taking GALCANEZUMAB GNLM who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is a less commonly reported adverse event for GALCANEZUMAB GNLM, but still significant enough to appear in the safety profile.
In addition to injection site erythema, the following adverse reactions have been reported for GALCANEZUMAB GNLM:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 1,086 FDA reports for GALCANEZUMAB GNLM. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 2.2% of all adverse event reports for GALCANEZUMAB GNLM, making it a notable side effect.
If you experience injection site erythema while taking GALCANEZUMAB GNLM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.